Patents by Inventor Stefan Sperl

Stefan Sperl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12209073
    Abstract: The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3?-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: January 28, 2025
    Assignee: Kiora Pharmaceuticals GmbH
    Inventors: Stefan Sperl, Lisa Plasser, Osama Suleiman, Christopher Daniel Scott, Susana Del Rio Gancedo, Joseph Stephen Harris
  • Publication number: 20240358544
    Abstract: The present disclosure provides a method of treating a human subject suffering from a retinal disorder, the method comprising administering to the eye of the subject via intravitreal injection a composition comprising a compound of formula (I) as described herein.
    Type: Application
    Filed: April 26, 2024
    Publication date: October 31, 2024
    Inventors: Brian STREM, Stefan SPERL, Eric DANIELS
  • Patent number: 12077517
    Abstract: The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3?-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: September 3, 2024
    Assignee: Panoptes Pharma GmbH
    Inventors: Stefan Sperl, Lisa Plasser, Osama Suleiman, Christopher Daniel Scott, Susana Del Rio Gancedo, Joseph Stephen Harris
  • Publication number: 20230286938
    Abstract: The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3?-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical compositions and kits comprising polymorphs of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a polymorph of the invention.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 14, 2023
    Inventors: Stefan SPERL, Lisa PLASSER, Osama SULEIMAN, Christopher Daniel SCOTT, Susana DEL RIO GANCEDO, Joseph Stephen HARRIS
  • Publication number: 20230285355
    Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
    Type: Application
    Filed: March 23, 2023
    Publication date: September 14, 2023
    Inventors: Stefan SPERL, Franz OBERMAYR
  • Publication number: 20230278979
    Abstract: The present disclosure provides salts of 3-(2,3,5,6-tetrafluoro-3?-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid. The present disclosure also provides pharmaceutical compositions comprising salts of the invention, and methods of treating, preventing, or ameliorating a disease or condition comprising administering a salt of the invention.
    Type: Application
    Filed: February 22, 2023
    Publication date: September 7, 2023
    Inventors: Stefan SPERL, Lisa PLASSER
  • Patent number: 11730716
    Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 22, 2023
    Assignee: KIORA PHARMACEUTICALS GMBH
    Inventors: Stefan Sperl, Franz Obermayr
  • Publication number: 20210052737
    Abstract: The present invention provides an ophthalmic composition comprising an active pharmaceutically compound non-covalently bound to albumin. The composition of the present invention is useful for treatment of ophthalmic diseases and disorders.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 25, 2021
    Inventors: Stefan SPERL, Franz OBERMAYR
  • Publication number: 20170071904
    Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
    Type: Application
    Filed: May 8, 2015
    Publication date: March 16, 2017
    Inventors: Stefan Sperl, Franz Obermayr
  • Patent number: 7807681
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: October 5, 2010
    Assignee: Wilex AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Publication number: 20100068272
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 18, 2010
    Applicant: WILEX AG
    Inventors: Stefan SPERL, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Patent number: 7659396
    Abstract: The invention relates to an improved method for the production of 3-amidino- or 3-guanidinophenylalanine derivatives, especially triisopropylphenyl-sulfonyl-substituted 3-amidino- or 3-guanidinophenylalanine derivatives.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: February 9, 2010
    Assignee: Wilex AG
    Inventors: Katja Wosikowski-Buters, Stefan Sperl, Joachim Sommer
  • Publication number: 20090286837
    Abstract: The present invention relates to novel compounds which inhibit urokinase-plasminogen activator (uPA), have a high bioavailability and can be administered orally, and to their use as therapeutic active substances for the treatment of disorders associated with urokinase and/or urokinase receptor, for example tumours and metastasis. The invention relates in particular to compounds containing oxadiazole groups.
    Type: Application
    Filed: August 29, 2006
    Publication date: November 19, 2009
    Inventors: Stefan Sperl, Jana Zimmermann, Klaus Koch
  • Patent number: 7608623
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: October 27, 2009
    Assignee: Wilex AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Patent number: 7538216
    Abstract: The invention relates to the use of derivatives of 3-guanidinophenylalanine as urokinase inhibitors for treating malignant tumors and metastasis.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: May 26, 2009
    Assignee: Wilex AG
    Inventor: Stefan Sperl
  • Publication number: 20090005562
    Abstract: The invention relates to an improved method for the production of 3-amidino- or 3-guanidinophenylalanine derivatives, especially triisopropylphenyl-sulfonyl-substituted 3-amidino- or 3-guanidinophenylalanine derivatives.
    Type: Application
    Filed: May 16, 2007
    Publication date: January 1, 2009
    Applicant: WILEX AG
    Inventors: Katja Wosikowski-Buters, Stefan Sperl, Joachim Sommer
  • Publication number: 20080261998
    Abstract: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 23, 2008
    Applicant: WILEX AG
    Inventors: Stefan Sperl, Markus Buergle, Wolfgang Schmalix, Katja Wosikowski, Bernd Clement
  • Patent number: 7247724
    Abstract: The invention relates to an improved method for the production of 3-amidinophenylalanine derivatives, especially triisopropylphenyl-sulfonyl-substituted 3-amidinophenylalanine derivatives.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: July 24, 2007
    Assignee: Wilex AG
    Inventors: Katja Wosikowski-Buters, Stefan Sperl, Joachim Sommer
  • Patent number: D974568
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: January 3, 2023
    Inventors: Wolfgang K. Meyer-Hayoz, Stefan Sperling, Dominic Kernen
  • Patent number: D1015542
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: February 20, 2024
    Assignee: Hemotune AG
    Inventors: Wolfgang K. Meyer-Hayoz, Stefan Sperling, Dominic Kernen